We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Compared to Estimates, Gilead (GILD) Q3 Earnings: A Look at Key Metrics
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) reported $7.05 billion in revenue for the quarter ended September 2023, representing a year-over-year increase of 0.1%. EPS of $2.29 for the same period compares to $1.90 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $6.77 billion, representing a surprise of +4.08%. The company delivered an EPS surprise of +19.90%, with the consensus EPS estimate being $1.91.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Product Sales- Genvoya- U.S: $433 million versus the four-analyst average estimate of $442.25 million. The reported number represents a year-over-year change of -13.8%.
Product Sales- Descovy- U.S: $460 million versus $485.83 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +3.6% change.
Product Sales- Odefsey- U.S: $257 million compared to the $247.18 million average estimate based on four analysts. The reported number represents a change of -6.9% year over year.
Product Sales- Vemlidy- U.S: $112 million compared to the $125.09 million average estimate based on four analysts. The reported number represents a change of -13.2% year over year.
Product Sales- Trodelvy- Total: $283 million compared to the $283.93 million average estimate based on nine analysts.
Product Sales- Descovy- Total: $511 million versus the nine-analyst average estimate of $521.73 million. The reported number represents a year-over-year change of +2.2%.
Product Sales- Odefsey- Total: $343 million compared to the $332.29 million average estimate based on nine analysts. The reported number represents a change of -8.3% year over year.
Product Sales- Vemlidy- Total: $228 million versus $214.25 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a 0% change.
Product Sales- Genvoya- Total: $503 million versus $544.15 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -16.2% change.
Product Sales- Biktarvy- Total: $3.09 billion versus the nine-analyst average estimate of $3.08 billion. The reported number represents a year-over-year change of +11.5%.
Revenues- Royalty contract and other revenues: $56 million compared to the $61.65 million average estimate based on nine analysts. The reported number represents a change of -12.5% year over year.
Product Sales- Total HCV: $438 million versus $450.49 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -16.4% change.
Shares of Gilead have returned +8.1% over the past month versus the Zacks S&P 500 composite's +1.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Compared to Estimates, Gilead (GILD) Q3 Earnings: A Look at Key Metrics
Gilead Sciences (GILD - Free Report) reported $7.05 billion in revenue for the quarter ended September 2023, representing a year-over-year increase of 0.1%. EPS of $2.29 for the same period compares to $1.90 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $6.77 billion, representing a surprise of +4.08%. The company delivered an EPS surprise of +19.90%, with the consensus EPS estimate being $1.91.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product Sales- Genvoya- U.S: $433 million versus the four-analyst average estimate of $442.25 million. The reported number represents a year-over-year change of -13.8%.
- Product Sales- Descovy- U.S: $460 million versus $485.83 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +3.6% change.
- Product Sales- Odefsey- U.S: $257 million compared to the $247.18 million average estimate based on four analysts. The reported number represents a change of -6.9% year over year.
- Product Sales- Vemlidy- U.S: $112 million compared to the $125.09 million average estimate based on four analysts. The reported number represents a change of -13.2% year over year.
- Product Sales- Trodelvy- Total: $283 million compared to the $283.93 million average estimate based on nine analysts.
- Product Sales- Descovy- Total: $511 million versus the nine-analyst average estimate of $521.73 million. The reported number represents a year-over-year change of +2.2%.
- Product Sales- Odefsey- Total: $343 million compared to the $332.29 million average estimate based on nine analysts. The reported number represents a change of -8.3% year over year.
- Product Sales- Vemlidy- Total: $228 million versus $214.25 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a 0% change.
- Product Sales- Genvoya- Total: $503 million versus $544.15 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -16.2% change.
- Product Sales- Biktarvy- Total: $3.09 billion versus the nine-analyst average estimate of $3.08 billion. The reported number represents a year-over-year change of +11.5%.
- Revenues- Royalty contract and other revenues: $56 million compared to the $61.65 million average estimate based on nine analysts. The reported number represents a change of -12.5% year over year.
- Product Sales- Total HCV: $438 million versus $450.49 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -16.4% change.
View all Key Company Metrics for Gilead here>>>Shares of Gilead have returned +8.1% over the past month versus the Zacks S&P 500 composite's +1.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.